Programme

April 4, 2013

   
10:30 Thrombosis and antithrombotic drugs in acute coronary syndromes
  Steen Dalby Kristensen (DK), Robert F. Storey (UK)
 
  • Current antiplatelet options in acute coronary syndromes (A.Parkhomenko)
  • Current options of anticoagulation in acute coronary syndromes (S Dalby Kristensen)
  • Pharmacogenetics and drug interactions with clopidogrel: testing or monitoring (RF Storey)
  • A critical comparison of new alternative treatment options (R. De Caterina)
   
13:00 Lunch Break
   
14:00

Long-term primary and secondary prevention of cardiovascular events  with antithrombotic drugs

  Lina Badimon (E), Sergio Coccheri (I)
 
  • Natural history of the athero-thrombotic plaque in different arterial districts (L. Badimon)
  • Aspirin in primary prevention: lights, shadows, and areas of uncertainty (S. Coccheri)
  • Antithrombotics in secondary   prevention strategy in high cardiovascular risk patients  (V.Netiazhenko)
  • Adding an anticoagulant to dual antiplatelet therapy (R. De Caterina)
   
16:30 Clinical cases
   
18:30 Dinner

 

April 5, 2013

   
08:30 Prophylaxis  and treatment of venous thromboembolism
  Grigori T Gerotziafas (F), Sabine Eichinger (A)
 
  • Prophylaxis and treatment of VTE in medical patients (GT Gerotziafas)
  • Clinical suspicion and diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE) (Y.Lutay)
  • Trends and perspectives in the treatment of DVT: acute phase and secondary prevention (S. Eichinger)
  • Risk stratification in acute PE and related therapeutic options (L.Chernuha)
   
11:00 Coffee Break
   
11:30 Systemic cardiogenic thromboembolism and stroke
  Alexander Parkhomenko (UA), Raffaele De Caterina (I)
 
  • Assessment and stratification of thromboembolic risk in cardiac patients (atrial fibrillation, valvular heart disease and heart failure) (G.Dzyak)
  • Atrial septal aneurism, patent foramen ovale and paradoxical embolism, diagnosis and treatment options (SD Kristensen)
  • “Upstream therapy” in atrial fibrillation: does it decrease the cardioembolic risk? (O.Sychov)
  • Prevention of cardioembolism with traditional and new anti-thrombotics (R. De Caterina)
   
14:00 Conclusion remarks and closing of the meeting
   
15:30

Joint working session of the Ukrainian Association of Cardiology and the International Society on Thrombosis and Haemostasis (ISTH), the Mediterranean League on Thromboembolic Disease (MLTD)